A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
a study on Solid Tumor
Solid Tumor melanoma HR+ breast cancer ovarian cancer prostate cancer colorectal cancer urothelial carcinoma adoptive cell therapy neoantigen T cell receptor T lymphocyte TCR-engineered T cells personalized cell therapy cell therapy immunotherapy gene therapy PD-1 non-small cell lung cancer head and neck squamous carcinoma HER2 negative breast cancer triple negative breast cancer IL-2 Neoplasms Aldesleukin Nivolumab Interleukin-2 NeoTCR-P1 adoptive cell therapy NeoTCR-P1 NeoTCR-P1 plus nivolumab NeoTCR-P1 plus IL-2
Lead Scientists at University of California Health
- Bartosz Chmielowski (ucla)
- Daniela Bota, MD (uci)
Professor, Neurology. Authored (or co-authored) 76 research publications.
- Mehrdad Abedi, MD (ucdavis)
Professor, Hematology and Oncology. Authored (or co-authored) 60 research publications.
- David Oh, MD (ucsf)
I am a physician-scientist experienced in clinical and translational laboratory efforts to understand and improve upon cancer immunotherapies.
- accepting new patients
- Start Date
- Completion Date
- PACT Pharma, Inc.
- Phase 1
- Study Type
- Last Updated